Published Articles & Presentations

The information in our publications and presentations should be considered accurate only as of the date of the publications or presentations. We disclaim any obligation to supplement or update the information in these publications and presentations.

To learn more about our innovative technology:

Publications Presentations

STOP 301: Open-label Safety and Tolerability of Chronic Intermittent Usage for 24/52 Weeks of INP104 [Nasal Dihydroergotamine Mesylate (DHE) Administered by Precision Olfactory Delivery (POD®) Device] in Migraine Headache

Migraine is a common, disabling disorder. IV DHE is an effective abortive therapy; however, the nasal formulation, Migranal®, has poor bioavailability and variable efficacy. We found INP104 (1.45 mg DHE) to have 4X greater systemic exposure than Migranal (2 mg)…

THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, PK and PD of L-dopa delivered to Parkinson’s Disease Patients in a Morning OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)

Poster presented at World Parkinson’s Congress 2019 in Kyoto, Japan Authors: Shrewsbury SB, Campbell J, Swardstrom M, Lehn A, Satterly KH, Hoekman J Objective: Impel NeuroPharma has developed the patient-friendly, self or caregiver actuated Precision Olfactory Delivery (IMPEL PODTM) device to achieve consistent upper nasal cavity drug delivery, rapid systemic uptake…

The Quantitative Scoring Scale – Nasal Mucosa (QSS-NM): A scale proposed for assessing olfactory mucosa changes following drug administration to the upper nasal space (olfactory epithelium) using a novel delivery device

A patient-friendly, self or caregiver actuated device to achieve consistent upper nasal space drug delivery, rapid systemic uptake and higher bioavailability than standard nasal sprays. The Quantitative Scoring Scale – Nasal Mucosa (QSS-NM) was developed, at FDA request, as a…

24 25 26